Metabolic tumour volume as a prognostic factor for oral cavity squamous cell carcinoma treated with primary surgery
Tóm tắt
Metabolic tumour volume (MTV) obtained from pre-treatment 18 F-fluorodeoxydeglucose positron emission tomography with computed tomography (PET-CT) has been validated as an independent predictive factor of outcomes in head and neck cancer patients (HNC) treated with primary chemoradiotherapy (CRT). However its role in patients treated with primary surgery has not yet been studied. To evaluate the prognostic value of MTV in patients treated with primary surgery for oral cavity squamous cell carcinoma (OCSCC). Demographic and survival data was obtained from patients diagnosed with OCSCC from 2008-2012 in Alberta, Canada. All patients included in the study had PET-CT scan before curative surgical resection. MTV and maximum standardized uptake value (SUVmax) value was delineated from pre-treatment PET-CT scans using Segami Oasis software (Columbus, OH). MTV and SUVmax were divided into intertertile thirds before statistical analysis to allow for in-group comparison of survival. A total of 80 patients were analyzed using SPSS ver. 20.0 (SPSS Inc, Chicago, IL). Five-year overall, and disease-free survival using Kaplan-Meier curves were 70% and 73% respectively. When the combined SUVmax (tumour primary and locoregional metastasis) was evaluated, it failed to predict overall (HR = 1.0, p = 0.99) or disease-free survival (HR = 1.0, p = 0.227). Conversely an increase in MTV of 17.5 mL (difference between the highest and lowest MTV tertile) was associated with a 12.4 fold increase in risk of disease recurrence (p < 0.001) and an 11.2 fold increase in the risk of death (p < 0.05). This study shows that MTV is an independent adverse prognostic factor for death and disease recurrence in OCSCC treated with primary surgery.
Tài liệu tham khảo
Davies L, Welch HG: Epidemiology of head and neck cancer in the United States. Otolaryngol Head Neck Surg. 2006, 135: 451-457. 10.1016/j.otohns.2006.01.029.
Canadian Cancer Society statistics. 2013. Available at: (accessed on March 1, 2013)., [http://www.cancer.ca/Canadawide/About%20cancer/Cancer%20statistics.aspx?sc_lang=en]
Dziegielewski PT, O'Connell DA, Szudek J, Barber B, Joshi A, Harris JR, Seikaly H: Neck metastases in oropharyngeal cancer: Necessity and extent of bilateral treatment. Head Neck. 2013, 35: 1461-1467.
La TH, Filion EJ, Turnbull BB, Chu JN, Lee P, Nguyen K, Maxim P, Quon A, Graves EE, Loo BW, Le QT: Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009, 74: 1335-1341. 10.1016/j.ijrobp.2008.10.060.
Tang C, Murphy JD, Khong B, La TH, Kong C, Fischbein NJ, Colevas AD, Iagaru AH, Graves EE, Loo BW, Le QT: Validation that metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2012, 83: 1514-1520. 10.1016/j.ijrobp.2011.10.023.
Dziegielewski PT, O'Connell DA, Klein M, Fung C, Singh P, Alex Mlynarek M, Fung D, Harris JR, Seikaly H: Primary total laryngectomy versus organ preservation for T3/T4a laryngeal cancer: a population-based analysis of survival. J Otolaryngol Head Neck Surg. 2012, 41 (Suppl 1): S56-64.
Moon SH, C JY, Lee HJ, Son Y, Baek C, Ahn YC, Park K, Lee K, Kim B: Prognostic value of 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: Comparisons of volume-based metabolic parameters. Head Neck. 2011, 229: 15-22.
Picchio M, Kirienko M, Mapelli P, Dell'Oca I, Villa E, Gallivanone F, Gianolli L, Messa C, Castiglioni I: Predictive value of pre-therapy (18)F-FDG PET/CT for the outcome of (18)F-FDG PET-guided radiotherapy in patients with head and neck cancer. Eur J Nucl Med Mol Imaging. 2014, 41: 21-31. 10.1007/s00259-013-2528-2.
Romesser PB, Qureshi MM, Shah BA, Chatburn LT, Jalisi S, Devaiah AK, Subramaniam RM, Truong MT: Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensity-modulated radiotherapy. Annal Nucl Med. 2012, 26: 527-534. 10.1007/s12149-012-0604-5.
Xie P, Yue JB, Zhao HX, Sun XD, Kong L, Fu Z, Yu JM: Prognostic value of 18-F-FDG PET-CT metabolic index for nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2010, 136: 883-889. 10.1007/s00432-009-0729-7.
Funk GF: A head and neck surgeon’s perspective on best practices for the use of PET/CT scans for the diagnosis and treatment of head and neck cancers. Arch Otolaryngol Head Neck Surg. 2012, 138: 748-752. 10.1001/archoto.2011.234.
Murphy JD, La TH, Chu K, Quon A, Fischbein NJ, Maxim PG, Graves EE, Loo BW, Le QT: Postradiation metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011, 80: 514-521. 10.1016/j.ijrobp.2010.01.057.
Alberta Heath Services.Cancer. Available at: (accessed March 1, 2013)., [http://www.albertahealthservices.ca/2171.asp]
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982, 5: 649-655. 10.1097/00000421-198212000-00014.
Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987, 40: 373-383. 10.1016/0021-9681(87)90171-8.
Edge SB: AJCC cancer staging handbook: from the AJCC cancer staging manual. 2010, Springer, New York
Gourin CG, Johnson JT: A contemporary review of indications for primary surgical care of patients with squamous cell carcinoma of the head and neck. Laryngoscope. 2009, 119: 2124-2134. 10.1002/lary.20619.
Zhang H, Dziegielewski PT, Biron VL, Szudek J, Al-Qahatani KH, O'Connell DA, Harris JR, Seikaly H: Survival outcomes of patients with advanced oral cavity squamous cell carcinoma treated with multimodal therapy: a multi-institutional analysis. J Otolaryngol Head Neck Surg. 2013, 42: 30-10.1186/1916-0216-42-30.
Lowry DR, M K: Prognostic Implications of HPV in Oropharyngeal Cancer. N Engl J Med. 2010, 363: 82-84. 10.1056/NEJMe1003607.
Ragin CC, Taioli E: Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer. 2007, 121: 1813-1820. 10.1002/ijc.22851.
Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010, 363: 24-35. 10.1056/NEJMoa0912217.
Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004, 350: 1945-1952. 10.1056/NEJMoa032641.
Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004, 350: 1937-1944. 10.1056/NEJMoa032646.
Lok BH, Setton J, Caria N, Romanyshyn J, Wolden SL, Zelefsky MJ, Park J, Rowan N, Sherman EJ, Fury MG, Ho A, Pfister DG, Wong RJ, Shah JP, Kraus DH, Zhang Z, Schupak KD, Gelblum DY, Rao SD, Lee NY: Intensity-modulated radiation therapy in oropharyngeal carcinoma: effect of tumor volume on clinical outcomes. Int J Radiat Oncol Biol Phys. 2012, 82: 1851-1857. 10.1016/j.ijrobp.2011.03.029.
Strongin A, Yovino S, Taylor R, Wolf J, Cullen K, Zimrin A, Strome S, Regine W, Suntharalingam M: Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2012, 82: 1823-1830. 10.1016/j.ijrobp.2010.10.053.
Tang C, Kligman F, Larsen CC, Kottke-Marchant K, Marchant RE: Platelet and endothelial adhesion on fluorosurfactant polymers designed for vascular graft modification. J Biomed Mater Res. 2009, 88: 348-358. 10.1002/jbm.a.31888.
Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, Macapinlac HA, Lee JJ, Ang KK, Chao KS, Chronowski GM, Frank SJ, Morrison WH, Rosenthal DI, Weber RS, Garden AS, Lippman SM, Schwartz DL: Prospective risk-adjusted [18 F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol. 2009, 27: 2509-2515. 10.1200/JCO.2008.19.3300.